Medtronic plc
MDTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. Valued at $122.04B, MDT is a large-cap name in its sector. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
Market Cap
$122.04B
Beta
0.57
P/E (TTM)
23.44
P/E (Fwd)
14.89
EPS (TTM)
$4.07
EPS (Fwd)
$6.41
ROE
10.7%
ROA
5.1%
Cash
$8.82B
Total Debt
$28.15B
Free CF
$5.41B
52W Change
1.4%
Annual Financials
Cash vs Debt
Where MDT stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, MDT finished 12.21% above its 150-day moving average ($83.98) and 8.40% above its 200-day moving average ($86.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDT overbought or oversold?
At the October 15, 2026 close, MDT's RSI(14) was 68.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Medtronic plc carries $28.15B in total debt against $8.82B in cash reserves — debt is roughly 3.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $5.41B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 10.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $31.23B to $36.36B.
MDT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Medtronic plc's trajectory.